Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CSPI...I agree. It is nice though to see cash @ over $27M ($3 a share) and still low/no debt.
We'll see what they have to say in the cc.
CSPI bottom line looks good. But what's going on with the top line?? Revenues down over 10% sequentially, and pretty flat vs last year (when there was no AZT). Lowest revenue in several quarters. So that's not great. Stock could still trade higher, but I think the disappointing revenue keeps a lid on it.
FACO($3.08) reports Q1 EPS $.18 vs $.03; revenue up 48% to $145M
I estimate trailing 12-month EPS at $.67, suggesting a P/E of less than 5. Also, book value is now $3.87/share
https://www.otcmarkets.com/stock/FACO/news/First-Acceptance-Corporation-Reports-Operating-Results-for-the-Quarter-Ended-March-31-2024?id=439631
CSPI...Nice report...CSP Inc. Reports Fiscal Second Quarter 2024 Operating Results; 23% Growth in Services Revenue Drives Gross Margin Percentage Expansion to 47% and Nearly Five-Fold Increase in Net Income
ARIA Zero Trust PROTECT ("AZT PROTECT™" or "AZT") Launch Broadens to Address Mid-Market Opportunity While Fortune 500 Pipeline Increases; Global Pharmaceutical Company Signs Multi-Million Dollar AZT Contract
LOWELL, MA / ACCESSWIRE / May 8, 2024 / CSP Inc. (NASDAQ:CSPI), an award-winning provider of cybersecurity AI-driven solutions (AZT), security and packet capture products, managed IT and professional / cloud services and technology solutions, today announced results for the fiscal second quarter ended March 31, 2024. The Company also announced that the Board of Directors declared a quarterly dividend of $0.03 per share payable June 12, 2024, to shareholders of record on the close of business on May 24, 2024.
Recent Achievements and Operating Highlights
Services revenue and high margin AZT sale contributes to the expanded gross margin and net income of $1.6 million for the fiscal second quarter
Recently published case study of AZT PROTECT™ in The Journal, an award-winning publication from Rockwell Automation and Our PartnerNetwork™, reached a subscriber base of over 50,000. The Journal educates the industrial automation market on leading-edge methods, trends, and technologies
CRN®, a brand of The Channel Company, named CSPi Technology Solutions to its Managed Service Provider (MSP) 500 list in the Security 100 category for 2024.
Continued strong balance sheet allows the company to rapidly invest in AZT PROTECT™ market development initiatives
ARIA Cybersecurity Wins Global Infosec Cybersecurity Product Award for AZT PROTECT at RSA
ARIA Cybersecurity Wins Prestigious Globee Cybersecurity Product Award for AZT PROTECT
"Our business continued to operate at a high level during the quarter, and across the board we are building a pipeline that is in line with, or well above our internal plans. As a result, we continue to execute a strategy designed to generate sustained long-term growth and profitability," commented Victor Dellovo, Chief Executive Officer. "The consistent performance of our Technology Solutions (TS) business and robust balance sheet is enabling investment in certain sales and marketing initiatives to generate the desired growth outcomes for the High Performance Products (HPP) business, mainly with the AZT offering."
"We believe our multi-pronged market awareness strategy for the AZT offering is demonstrating the need and attractiveness to large Fortune 500 global brands. The effort has resulted in landing a major AZT customer - a global pharmaceutical company. With a dedicated sales team focused on this enterprise segment, we recently added three sales representatives to target mid-market companies while we build partnerships with organizations addressing both markets. Earlier this month, we also achieved another significant milestone with our partner Rockwell, and the publication of an AZT PROTECT™ deployment case study within a Fortune 500 company. This article published in The Journal is distributed to over 50,000 subscribers - readers that heavily rely on knowing the latest and best solutions to meet today's cybersecurity threats and challenges.
As we move forward, we believe the focus of our direct sales team and leveraging our new and expanding partnerships is going to significantly raise the profile of the AZT offering. Despite being less than a year removed from the launch, we are building traction in the market and the level of enthusiasm remains high, as does the new business lead pipeline. We are optimistic about the opportunities we have with AZT and look forward to the second half of our fiscal year."
Fiscal 2024 Second Quarter Results
Revenue for the fiscal second quarter ended March 31, 2024, was up slightly to $13.7 million compared to revenue of $13.3 million for the fiscal second quarter ended March 31, 2023. Services revenue constituted $5.2 million of overall sales, an increase of 23% compared to services revenue of $4.3 million in the year-ago fiscal second quarter. Gross profit for the three months ended March 31, 2024, was $6.5 million, or 47% of sales, compared to $5.0 million, or 38% of sales, representing a 9% improvement as higher margin services revenue along with the high margin AZT sale fueled the growth. The Company reported net income of $1.6 million, or $0.16 per diluted common share for the fiscal second quarter ended March 31, 2024, compared to net income of $0.3 million, or $0.03 per diluted common share for the fiscal second quarter ended March 31, 2023. Earnings per diluted common share are retroactively adjusted for the effects of a stock split effected in the form of a 100% stock dividend which occurred during the second fiscal quarter of 2024.
The Company had cash and cash equivalents of $27.1 million as of March 31, 2024, providing it with the resources to invest in market awareness and growth initiatives for its products and services, including the transformative AZT offering.
Fiscal Year 2024 Six Month Results
Revenue for the fiscal six months ended March 31, 2024, was $29.1 million compared with revenue of $31.6 million in same prior year period. Gross profit for the fiscal six months ended March 31, 2023, was $10.6 million, or 36% of sales compared with $10.8 million, or 34% of sales, reflecting a more favorable product mix and benefiting from the higher margin services revenue in the 2024 fiscal second quarter. The Company reported net income of $1.5 million, or $0.16 per diluted common share in the fiscal six months ended March 31, 2024 compared with net income of $1.3 million, or $0.14 per diluted common share for the fiscal six months ended March 31, 2023.
Conference Call Details
CSPi Chief Executive Officer Victor Dellovo and Chief Financial Officer Gary W. Levine will host a conference call at 10:00 a.m. (ET) today, May 8, 2024, to review CSPi's financial results and provide a business update. To listen to a live webcast of the call, the event link is https://www.webcaster4.com/Webcast/Page/2912/50580. Individuals also may listen to the call via telephone, by dialing 77-545-0523 or 973-528-0016 and use the Participant Access Code: 533105 when greeted by the live operator. For interested parties unable to participate in the live call, an archived version of the webcast will be available for approximately one year on CSPi's website.
Reasercher59, as you said the cost basis is shown by lot. I have to be honest since I generally sell my whole position more times than not, never looked into the tax feautures because it never really applies to me. Hope this helps. All is just my opinion, and I could always be wrong though.
IART
This is standard operating procedure. When a stock falls off a cliff the analysts take down there price targets. This isn't a IART thing it happens all the time, if IART stock starts going up the price target will suddenly climb out of nowhere (Which is why I don't have much value on analyst price targets). But if you read the post researcher had on it today, reading between the lines they don't believe the company will hit guidance. In fairness I think the reaction by the market at this point is like you told us about Boston a year ago, a year later your more clueless than a year ago. so why should I trust anything you say. They have to show they should be trusted at thispoint, they cannot come in and tell us they need to lower guidance again, and they haven't figured out the integra skin business. After awhile you have to do something right. Now I think they will and management although having other problems, I think has no clue how to fix boston, but the rest of the business they have a firm handle on. Could I be wrong we will find out. The good news is we now know Boston isn't gonna be the thing that destroy guidance or the share price this time, everyone is factoring boston completely out at this point. All is just my opinion, and I could always be wrong though.
SSKMP Managed Index (As Of 5/7/24)
Daily Performance
+0.49%
YTD Performance
+1.22%
Overall Performance
+477.50% (Including Options Trading +341.48%)
HALO
I was selling my shares here and there AH. They missed on revenues, and In the CC royalities are suppose to be flat sequentially I think I heard. I was under the opinion they would hit the high end of revs, and possibly beat the eps number. Now I think they will hit the lower end of revs, and eps will be within the range. HALO is up against resistance in the $42-43 range., and I don't think a .79 quarter with a miss on the top line, will be enough to break it through resistance. I Basically had a average cost of about $34 and sold about $42 avg, so I had a nice profit. clearly they are going to be heavy back half weighted, was a litte disappointed not to see a ramp up in q2, and thought revs would be a little better in q1. I will buyback on weakness say somewhere around $37-38 I would be a buyer again. Anyways time will tell if I'm making the right decision. All is just my opinion, and I could lways be wrong though.
HRTG - Some insider buying by the CEO, CFO, and a director after the stock got crushed upon releasing their earnings report. One was for 50,000 shares.
https://www.sec.gov/Archives/edgar/data/1598665/000095017024054573/xslF345X05/ownership.xml
https://www.sec.gov/Archives/edgar/data/1598665/000095017024054573/xslF345X05/ownership.xml
https://www.sec.gov/Archives/edgar/data/1598665/000095017024054552/xslF345X05/ownership.xml
VNDA - are they re-considering the proposal?
WASHINGTON, May 7, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (NASDAQ:VNDA) today confirmed that it has received a revised unsolicited proposal from Future Pak, LLC ("Future Pak") to acquire the Company. The revised proposal consists of a $7.25 to $7.75 per share in cash plus certain Contingent Value Rights ("CVRs"). The amended proposal follows Vanda's review and rejection of a prior unsolicited proposal from Future Pak to acquire the Company for $7.25-$7.75 per share.
Consistent with its fiduciary duties, and in consultation with its independent financial and legal advisors, Vanda's Board of Directors will carefully review and evaluate the revised unsolicited proposal to determine the course of action that it believes is in the best interests of Vanda and its shareholders.
Vanda does not intend to comment further on the revised, unsolicited proposal before the Board has completed its review.
There is no action for shareholders to take at this time.
https://capedge.com/news/benzinga/38673993/vanda-pharmaceuticals?fromCompany=1347178
HALO (41.21) beats Q1 estimates by 14% and maintains annual guidance -
briefing -
Halozyme Therapeutics beats by $0.10, misses on revs; reaffirms FY24 EPS guidance, revs guidance (41.21 +0.35) :
Reports Q1 (Mar) earnings of $0.79 per share, excluding non-recurring items, $0.10 better than the FactSet Consensus of $0.69; revenues rose 20.8% year/year to $195.88 mln vs the $199.74 mln FactSet Consensus.
Co reaffirms guidance for FY24, sees EPS of $3.55-3.90, excluding non-recurring items, vs. $3.52 FactSet Consensus; sees FY24 revs of $915-985 mln vs. $954.43 mln FactSet Consensus.
Announced new $750 million share repurchase program in February.
Schwab - ok I just bought a few tiny positions at Schwab ahead for my transfer from Ameritrade. I see the cost basis shown by lot. Also the account settings provide the tax lot optimizer for lot selection. Ameritrade has displays by Realized Gain/Loss, Unrealized and Pending Settlement. In pending settlement one can override the automated tax lot selection. I hope Schwab also offers this override feature. I'll be looking for it when I make my first sale .....
CXDO...Not too shabby...Crexendo Announces First Quarter 2024 Results
PHOENIX, AZ / ACCESSWIRE / May 7, 2024 / Crexendo, Inc. (NASDAQ:CXDO), an award-winning premier provider of cloud communication platform and services, video collaboration and managed IT services designed to provide enterprise-class cloud solutions to any size business, today announced financial results for the first quarter ended March 31, 2024.
First Quarter Financial highlights:
Total revenue increased 14% year-over-year to $14.3 million
GAAP net income of $434,000, or $0.02 per basic common share and $0.01 per diluted common share
Non-GAAP net income of $1.9 million, or $0.07 per basic common share and $0.06 per diluted common share
Financial Results for the First Quarter of 2024
Total Revenue: Consolidated total revenue for the first quarter of 2024 increased 14%, or $1.8 million, to $14.3 million compared to $12.5 million for the first quarter of 2023.
Service Revenue: Consolidated service revenue for the first quarter of 2024 increased 10%, or $0.7 million, to $7.8 million compared to $7.1 million for the first quarter of 2023.
Software Solutions Revenue: Consolidated software solutions revenue for the first quarter of 2024 increased 25%, or $1.0 million, to $5.1 million compared to $4.1 million for the first quarter of 2023.
Product Revenue: Consolidated product revenue for the first quarter of 2024 increased 6%, or $0.1 million, to $1.3 million compared to $1.2 million for the first quarter of 2023.
Operating Expenses: Consolidated operating expenses for the first quarter of 2024 decreased 2%, or $(0.2) million, to $13.8 million compared to $14.0 million for the first quarter of 2023.
Net Income/(Loss): The Company reported net income of $0.4 million for the first quarter of 2024, or $0.02 per basic common share and $0.01 per diluted common share, compared to net loss of $(1.6) million, or $(0.06) loss per basic and diluted common share for the first quarter of 2023.
Non-GAAP: Non-GAAP net income of $1.9 million for the first quarter of 2024, or $0.07 per basic common share and $0.06 per diluted common share, compared to non-GAAP net income of $0.6 million or $0.02 per basic and diluted common share for the first quarter of 2023.
EBITDA and Adjusted EBITDA: EBITDA for the first quarter of 2024 of $1.3 million compared to a loss of $(0.7) million for the first quarter of 2023. Adjusted EBITDA for the first quarter of 2024 of $2.0 million compared to $0.7 million for the first quarter of 2023.
Cash and Cash Equivalents: Total cash and cash equivalents at March 31, 2024 was $11.0 million compared to $10.3 million at December 31, 2023.
Cash Flow: Cash used for operating activities for the first quarter of 2024 was $(0.2) million compared to $(1.6) million used for the first quarter of 2023. Cash used for investing activities for the first quarter of 2024 was nill compared to $(0.0) million used for the first quarter of 2023. Cash provided by financing activities for the first quarter of 2024 was $0.8 million compared to cash used in financing activities of $(0.2) million for the first quarter of 2023.
Management Commentary
"Our superb performance in the first quarter of 2024 reflects our unwavering commitment to innovation, operational excellence, and delivering value to our shareholders and customers. We are very pleased with the strong financial results, including a 14% year-over-year organic increase in total revenue to $14.3 million as well as GAAP profitability." Said Jeff Korn Crexendo Chief Executive Officer and Chairman of the Board. "Our revenue growth remains robust, driven by a 25% growth in the software solutions segment as well as a double digit increase in telecom service revenue which equated to very solid performance across all revenue segments."
Korn added "We remain steadfast in our efforts to streamline costs and improve operational effectiveness. Our efforts resulted in GAAP net income of $434,000, non-GAAP net income of $1.9 million and Adjusted EBITDA of $2.1 million, demonstrating our ability to deliver profitable growth and create value for our shareholders. This is now the third quarter in a row of GAAP profitability which is particularly meaningful. Looking ahead, we remain focused on driving organic growth, pursuing larger opportunities, and exploring accretive acquisitions to further accelerate our expansion. Our strong performance in the first quarter of 2024, coupled with the demand for our services positions us well for continued success. We are confident in our ability to sustain our growth momentum and capitalize on market opportunities, supported by our dedicated team and strong market positioning. I remain highly excited and enthusiastic about our future."
Conference Call
Crexendo management will hold a conference call today, May 7, 2024, at 4:30 PM Eastern time to discuss these results. Company CEO Jeff Korn, CFO Ron Vincent, and President and COO Doug Gaylor will host the call, followed by a question-and-answer period.
FTK...Flotek Announces First Quarter 2024 Results Reflecting Improved Profitability
HOUSTON, May 7, 2024 /PRNewswire/ -- Flotek Industries, Inc. ("Flotek" or the "Company") (NYSE: FTK) today announced operational and financial results for the quarter ended March 31, 2024, highlighted by significant improvement in profitability metrics as compared to the first quarter of 2023.
Financial Summary (in thousands, except per share amounts)
Three months ended March 31,
2024
2023
% Change
Total Revenues
$ 40,374
$ 48,007
(16) %
Gross Profit
$ 8,821
$ 1,880
369 %
Adjusted Gross Profit (1)
$ 10,075
$ 2,647
281 %
Net Income
$ 1,562
$ 21,343
(93) %
Diluted Income (Loss) Per Share
$ 0.05
$ (0.12)
n/a
Adjusted EBITDA (1)
$ 4,026
$ (3,851)
n/a
First Quarter 2024 Highlights
Reported net income of $1.6 million compared to net income of $21.3 million for the first quarter of 2023. Net income for the first quarter of 2023 benefited from $30.6 million in non-cash gains. Excluding these non-cash gains, first quarter 2024 net income improved by $10.8 million.
Delivered significant year-over-year improvements in gross profit, adjusted gross profit(1) and adjusted EBITDA(1) of $6.9 million, $7.4 million and $7.9 million, respectively.
Realized gross profit margin and adjusted gross profit margin(1) of 22% and 25%, respectively.
Achieved the 3rd consecutive quarter of net income and 11th consecutive quarter of improvement in adjusted EBITDA(1) as a percentage of revenue.
Reduced borrowings outstanding under the Asset Based Loan by 58% (or $4.4 million) compared to year-end 2023.
Full Year 2024 Profitability Outlook
As a result of the numerous cost reductions and efficiency gains implemented throughout 2023, the Company expects a substantial increase in margins compared to 2023. In 2023, our gross margin was 13% and our net income was $24.7 million. Flotek expects 2024 adjusted gross profit margin(2) to range between 18% and 22%, as compared to 2023 adjusted gross profit margin(1) of 15%. The Company expects 2024 adjusted EBITDA(2) to range between $10 million and $16 million as compared to $1.5 million in 2023(1).
Management Commentary
Chief Executive Officer Dr. Ryan Ezell commented, "Our first quarter results continue the positive financial and operational trends that began during 2022. We achieved our third consecutive quarter of net income. Adjusted EBITDA(1) during the quarter exceeded the entire year of 2023. Using the mid-point of our guidance, we expect a nearly 800% increase in annual adjusted EBITDA(2) versus 2023(1).
During the quarter we realized 19% sequential growth in our ProFrac related revenue while our data analytics segment revenues increased 18% from the fourth quarter of 2023. While our first quarter external chemistry customer sales realized 27% year over year growth, they declined sequentially, which is consistent with the first quarter in each of the last three years. We expect these revenues will show a substantial increase during the second quarter and we anticipate annual growth in external chemistry customer sales for 2024.
Our numerous financial improvements continue to validate the initiatives executed over the past 18 months aimed at building a resilient business that can sustain profitability through the volatility inherent in our industry."
First Quarter 2024 Financial Results
Revenue: Flotek reported total revenues of $40.4 million for the first quarter 2024, which was a decrease of $7.6 million, or 16%, compared to total revenues of $48.0 million for the first quarter 2023. The decline in revenue compared to the first quarter 2023 was the result of lower related party activity that was partially offset by a 13% increase in revenue from external customers.
Revenue from external chemistry customers during the first quarter 2024 declined by approximately $6.0 million as compared to the fourth quarter 2023 due primarily to normal seasonal declines. The Company anticipates external chemistry customer revenues to increase significantly in the second quarter 2024.
Revenue associated with the Company's data analytics segment increased to $1.7 million, an 18% improvement as compared to the fourth quarter 2023. Revenues from data analytics totaled $2.5 million during the first quarter 2023.
Gross Profit: The Company generated gross profit of $8.8 million during the first quarter 2024 as compared to gross profit of $1.9 million for the first quarter 2023. The improvement in first quarter 2024 gross profit was the result of successful initiatives to drive cost improvements with respect to freight, logistics and materials, and revenue attributable to the estimated annual minimum chemistry purchase requirements contained in the ProFrac supply agreement. The measurement period during 2023 for annual minimum chemistry purchase requirements was June 1, 2023 through December 31, 2023.
Adjusted Gross Profit (Non-GAAP)(1): Flotek generated adjusted gross profit of $10.1 million during the first quarter 2024 compared to adjusted gross profit of $2.6 million for the first quarter 2023. Adjusted gross profit excludes non-cash items, primarily amortization of contract assets.
Selling, General and Administrative ("SG&A") Expense: SG&A expense totaled $6.1 million for the first quarter 2024 compared to $6.5 million for the first quarter 2023. The improvement was the result of lower personnel costs and professional fees during the 2024 period.
Net Income and EPS: Flotek reported net income of $1.6 million, or $0.05 per diluted share, for the first quarter 2024. This compares to net income of $21.3 million, or $(0.12) per diluted share, for the first quarter 2023. Net income for the first quarter 2023 benefited from a $26.1 million non-cash gain related to the fair value adjustment of the Company's convertible notes, as well as a $4.5 million gain from the partial forgiveness of the Company's PPP loan.
Adjusted EBITDA (Non-GAAP)(1): Adjusted EBITDA was $4.0 million in the first quarter 2024 as compared to negative $3.9 million in the first quarter 2023.
(1) A non-GAAP financial measure. See the "Unaudited Reconciliation of Non-GAAP Items and Non-Cash Items Impacting Earnings" section in this release for more information, including reconciliations to the most comparable GAAP measures.
(2) A non-GAAP financial measure. See the "Unaudited Reconciliation of Non-GAAP Items and Non-Cash Items Impacting Earnings" section in this release for more information, including reconciliations to the most comparable GAAP measures. We are unable to reconcile this forward-looking non-GAAP financial measure to the most directly comparable GAAP financial measure without unreasonable efforts, as we are unable to predict with a reasonable degree of certainty the impact of certain items that would be expected to impact the GAAP financial measure, including, among other items, the future amortization of our contract assets, certain stock-based compensation costs and the impact of the revaluation of certain liabilities, which is based upon our future stock price. These items do not impact the non-GAAP financial measure.
Conference Call Details
Flotek will host a conference call on May 8, 2024, at 9:00 a.m. CT (10:00 a.m. ET) to discuss its first quarter 2024 results. Participants may access the call through Flotek's website at www.flotekind.com under "News" within the Investor Relations section or by telephone toll free at 1-800-836-8184 (international toll: 1-646-357-8785) approximately five minutes prior to the start of the call. Following the conclusion of the conference call, a recording of the call will be available on the Company's website.
An updated corporate presentation that will be referenced on the call will be posted to the Investor Relations section of Flotek's website at www.flotekind.com prior to the start of the earnings conference call.
About Flotek Industries, Inc.
Flotek Industries, Inc. is an advanced technology-driven, green chemical and data analytics company providing unique and innovative completion solutions that have a proven, positive impact on sustainability and reducing the overall environmental impact of energy on air, land, water and people. Flotek has an intellectual property portfolio of over 170 patents and a global presence in more than 59 countries throughout North America, Latin America, the Middle East and North Africa. Flotek has established collaborative partnerships focused on sustainable and optimized chemistry and data solutions which improve well performance and allow its customers to generate higher returns on invested capital.
Flotek is based in Houston, Texas and its common shares are traded on the New York Stock Exchange under the ticker symbol "FTK". For additional information, please visit www.flotekind.com.
SSK - does Schwab have a cost basis display for portfolio holdings by lot ? At Ameritrade one can click on a security to see each purchase date, the lot size and gain or loss. One can also choose specific lots for sales for tax purposes.
Are these feature offered by Schwab ???
IART - I think it will be range bound in the mid to high $20's for the coming few months. Management has lost credibility and sentiment has changed from bullish to bearish on the stock.
CURI 1.28 Up but on oddly low volume prior to earnings release today AH. Has been actively traded and volatile in recent weeks but I have no clue if earnings will be decent. I'm holding with my fingers crossed.
VNDA ... Future Pak really wants 'em, ... Future Pak has boosted its acquisition offer for Vanda Pharmaceuticals (NASDAQ:VNDA) to include contingent value rights in addition to the previously announced increased cash consideration of $7.25 to $7.75 per share.
Vanda shares are up ~15% in Tuesday morning trading.
Future Pak said that its latest offer represents a total consideration of $11.62 to $12.12 per share. If full CVRs are exercised, it also represents a premium of 140% to 150% to Vanda's closing price of $4.84 on May 6.
The CVRs are valued at up to $260M, according to Future Pak.
OMIC .445 - one of our prominent board-members frequently refers to "manipulation" in these markets...well I'm seeing a setup here where one might take advantage?
OMIC has until "July 15, 2024" to get the pps above $1.00 for 10 days...
On July 17, 2023, the Company received a letter from Nasdaq indicating that the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1) because the closing bid price per share for the Company’s common stock had closed below $1.00 for the previous 30 consecutive business days (the “Minimum Bid Price Requirement”). In response, the Company filed an application to transfer the listing of its common stock from the Nasdaq Global Select Market to the Nasdaq Capital Market. As a result of the Approval, the Company has been granted an additional 180-day compliance period, or until July 15, 2024, to regain compliance with the Minimum Bid Price Requirement. To regain compliance with the Minimum Bid Price Requirement and qualify for continued listing on the Nasdaq Capital Market, the minimum bid price per share of the Company’s common stock must be at least $1.00 for at least ten consecutive business days during the additional 180-day compliance period. If the Company fails to regain compliance during the additional compliance period, then Nasdaq will notify the Company of its determination to delist the Company’s common stock, at which point the Company would have an opportunity to appeal the delisting determination to a Nasdaq Hearings Panel.
https://capedge.com/filing/1850906/0000950170-24-045597/OMIC-DEF14A
...or they intend to enact a R/S...so my risk without any "manipulation" (to a pps over a buck) will be to hold a $5 or $10 reverse-split stock still trading at approx. 1/3 of cash...
R59- IART
Does it make any sense to you, that the company was posting around $3 in eps in 2021, when the stock was $75, and now is guiding for $3.06 in eps for 2024, yet the stock price is $25 ? I understand that back then, the Boston Factory had no issues, and that margins from the 2 products made there were higher than normal. However, I have a hard time believing that regardless of IARTs other products and latest acquisition pretty much making up for the earnings lost from the Boston Factory closure, that the company is still worth 1/3 the value. I mean, what's the reasoning ? That we now can't trust guidance from the company, as they haven't done a very good job in getting the Boston Factory back on line. You know Re, you once told me years ago, that analysts will often gang up on a company with additional downgrades, even after the stock has gotten decimated, and that often marks a bottom for the stock.
maxluke, I hadn't seen TSBX or IKNA...keep the newby nosedive cashfat-biobusts coming, thanks.. With all the recent biotech IPO's of the past few years, surely more will nosedive into lucrative oppurtunities.
I also continue to hold a sizeable position in OMIC and into a probable Reverse-Split which will certainly be advantageous to OMIC imo, altho I fully expect the madding crowd might take it the wrong way - lol.
XLO, AMLX, and VNDA are my fav's du jour...
especially VNDA @ 5.60 - approx. $7.00 BV, a $7 - $12 buyout offer on the table, a PDUFA date for "tradipant" on 9/18/24, Real Revenue/Minimal Burn, and very lucrative option premiums...and an announced Q1 filing after tomorrow's close which I fully expect them to re-hype all of the above.
RPHM - watching this one now too, thanks
Was all out of ELYM by ~8.50 before it ran to 11. No idea who buys this stuff after it's run so much.
I think I like these a bit better than RPHM at the moment (not sure if you had any thoughts on these):
IKNA - initiated position in the low 1.30s
TSBX - reloaded around 2.70.
BOLT - intriguing, but no position
Still holding a bit of SNSE, full position of OMIC, and CMRX
I've had my best year in the biocrap sector yet, but not sure what's next. There's still tons below cash value. I remember back in the late 2010s when there were only a few that traded below cash, then 2022 hit and there were more than ever below cash. There's less now than in 2022, but still plenty to choose from.
SS- IART- Analyst downgrades
Why are the analysts knocking the price targets down by 40% ? I mean the stock has been pulverized already, and now down to a 8 PE going forward ? I have a hard time believing the problems with the Boston Factory has caused this stock to go down 70% the last two years, and there seems to be no bottom, no matter what guidance the company gives !
IART +1.66 to 24.80 .... here are the analyst comments, fwiw - the price target cuts are rather severe.
fly -
Integra LifeSciences price target lowered to $25 from $37 at Truist
Truist analyst Richard Newitter lowered the firm's price target on Integra LifeSciences to $25 from $37 and keeps a Hold rating on the shares. The firm is adjusting its model to reflect the company's further Boston facility restart delay, also removing its previously modeled contributions, the analyst tells investors in a research note. Integra's Acclarent revenue offset the impact on the top line but not on margins, the firm states, adding that the stock's valuation discount is justified given the accumulating execution errors on the part of the company as well as its peers' faster revenue and growth prospects.
08:25 EDT IART
Integra LifeSciences price target lowered to $24 from $37 at Morgan Stanley
Morgan Stanley lowered the firm's price target on Integra LifeSciences to $24 from $37 and keeps an Underweight rating on the shares. An overall in line Q1 was "overshadowed" by another negative update on Boston facility commercialization, says the analyst, who continues to see Integra shares underperforming relative to peers over the next 12 months.
06:56 EDT IART
Integra LifeSciences price target lowered to $40 from $49 at JMP Securities
JMP Securities analyst David Turkaly lowered the firm's price target on Integra LifeSciences to $40 from $49 and keeps an Outperform rating on the shares following the Q1 results. Management noted that a third-party audit was recently conducted at its Boston facility, and the observations extended the expected relaunch timeframe for SurgiMend, PriMatrix, and several private label lines indefinitely, the analyst tells investors in a research note. While the magnitude of the financial update was not that significant, it is likely the open-ended nature of the situation from a timing standpoint that sent the stock down 20%, which JMP views as overdone.
06:45 EDT IART
Integra LifeSciences price target lowered to $26 from $42 at BofA
BofA lowered the firm's price target on Integra LifeSciences to $26 from $42 and keeps an Underperform rating on the shares. Integra does not expect to get its Boston facility back online in 2024 and the new findings from the Boston audit "are the latest in a series of setbacks" over the last two years, says the analyst, who adds that "investors have grown increasingly frustrated amidst the numerous delays." The company's updated FY24 sales guidance "looks too aggressive" and implies a second half sales ramp that "may be hard to hit," the analyst contends.
Integra LifeSciences price target lowered to $25 from $45 at Wells Fargo
Integra LifeSciences downgraded at Wells on pushout of Boston facility restart
As previously reported, Wells Fargo downgraded Integra LifeSciences to Equal Weight from Overweight with a price target of $25, down from $45. The firm had previously upgraded Integra as it had believed that the Boston facility restart would represent an inflection point and drive potential EPS upside from a return of high margin products. However, management noted that it no longer expects to resume Boston commercial distribution in 2024 as the third party audit yielded more findings than expected and more work is needed. Given that restart is not expected in 2024 and management is still working on a detailed plan without a specific timeline offered, the firm is moving to the sidelines, the analyst tells investors.
Bought some ML at 75. It is still down 75% from IPO price nearly 4 years ago, and has made the first quarterly profit, $0.6 per share, due to revenue growth and cost cut. It has increased revenue every quarter in the past a few years.
Valuemind for what it's worth I was being sarcastic with surprise, surprise. LOL.
Why surprised? More often than not, analysts give downgrade at bottom and upgrade at top.
IART
I can't say I deserve any congratulations as the stock has been a unmitigated disaster since I brought it overall. What I found funny today is the analyst were in a rush to downgrade it this morning and lower price targets and surprise, surprise, the stock actually troughs from the absurd overreaction to the stock yesterday in my opinion.
Thanks on KLNG. Aha I used to own DPDW on & off for years. Probably the same lumpy quarters but the earnings PR mentioned continued strong order intake in Q1. Plus they won this multimillion dollar contract in April after Q1 ended-
https://finance.yahoo.com/news/koil-energy-secures-major-contract-172000974.html
I bought a few in the .60's. KLNG earned .05/share in Q1 and they've got some easy comps coming up. If we see any more quarters like Q1 (or maybe even better), the stock could pop up to $1+. But not exactly one to load up on.
MLR - Thanks for article, Nelson. The stock hit a new-52-week high today. I added some recently after reading the letter to shareholders which I thought was very positive. The link is below:
https://www.sec.gov/Archives/edgar/data/924822/000110465924052952/tm2412664d2_ars.pdf
KLNG - This is the old DPDW. I held this one for a long time with disappointing results. I think this was one of 10bagger's stocks. They do have a new CEO now, so maybe things are changing. I tried to buy some .55s this morning, but that didn't happen. The CEO does sound pretty positive about things fwiw. From the PR this morning:
More likely than not, it is un-sustainable.
Great buy at 22.89, congratulation. I followed you and got some yesterday.
CXDO...Crexendo Selects Oracle Cloud Infrastructure to Support Unprecedented Company Growth
PHOENIX, AZ / ACCESSWIRE / May 7, 2024 / Crexendo®, Inc. (NASDAQ:CXDO), an award-winning premier provider of cloud communication platforms and services, video collaboration, and managed IT services designed to provide enterprise-class cloud solutions to any size business, today announced availability of its hosted services globally on Oracle Cloud Infrastructure (OCI), marking a pivotal moment in Crexendo's rapid growth and geographic expansion.
Working with OCI will help simplify Crexendo partners' business of operating a unified communications platform, and the security-first approach of OCI allows customers to not have to compromise between reliability, security, and cost. With more than 4.5 million users on Crexendo's NetSapiens platform, this move offers unparalleled flexibility, enabling partners to use the software platform according to their preferences, whether in their own cloud environment or within Oracle's secure cloud.
"Our customers celebrate having the industry's leading platform, and we sought to match this level of performance with the industry's leading hosting partner in OCI," said Jeff Korn, CEO and chairman, Crexendo. "We rigorously assessed where our customers would receive the highest performance and the decision to partner with Oracle was unequivocal."
Korn continued, "OCI's distributed cloud architecture enables us to think globally with location independence, expanding our market reach and enhancing the customer experience. The superior price-performance of OCI enables us to deliver incredible value to our customers, solidifying our position as a trusted partner in their journey. With more than 430,000 customers trusting Oracle, Crexendo joins a prestigious community of innovators and industry leaders. Together, we're redefining the future of cloud communication solutions and revolutionizing the way businesses communicate and connect in today's digital age."
"We're excited that Crexendo has selected Oracle Cloud Infrastructure as their cloud platform of choice for their unified communications as a service offering," said David Hicks, group vice president, ISV Business and Marketing Development, Oracle. "OCI will help support Crexendo's current and future business plans. Specifically, OCI's superior price-performance and data egress advantages, its global datacenter footprint, and its price consistency give Crexendo a predictable platform for international expansion of their business."
https://finance.yahoo.com/news/crexendo-selects-oracle-cloud-infrastructure-130000700.html
Anyone follow KLNG? Excellent Q1 results, but not sure how sustainable-
https://finance.yahoo.com/news/koil-energy-solutions-inc-announces-201000557.html
VNDA 5.20 - Future Pak Increases Bid for Vanda Pharmaceuticals to Include CVRs in Addition to $7.25 to $7.75 Per Share in Cash
https://capedge.com/news/benzinga/38668822/future-pak-increases?fromCompany=1347178
CXDO...Crexendo is a well oiled growth machine with a strong track record. This will remain my top long term hold until something changes. (Was waaaaay overweight the stock heading into this year, and took advantage of the pop to higher prices to sell over 1/2. But since I've accummulated some back in the low/mid $'4's and currently CXDO is @ approx 30% my portfolio).
Here's a morsal from their last cc's Q&A ...
Mike Latimore
One more quick one here. I guess can you provide any color on just how January and February have played out from a bookings perspective? Kind of is it normal seasonality, better or worse? Just how are you -- how did you see January and February relative to kind of those normal months at the start of the year?
Jeffrey Korn
Mike, as you know, we don't give guidance, but we don't give guidance, Mike. But as I said in my comments, I'm very pleased with the results we're seeing for Q1.
So I don't want to say much more than that. But I wouldn't have indicated that we expect double-digit growth if we didn't see Q1 going well.
Doug Gaylor
Yes. And I would tell you, Mike, that sales momentum is very strong right now.
We continue to add new reseller partners out there, and our funnel for sales opportunities is as strong as it's ever been.
So we're not seeing any slowdown in opportunities out there and bookings continue to have great momentum.
Earnings after the close.
We'll see what happens.
MLR positive article from SA, article ex graphics below:
Miller Industries Can Keep Pulling Itself Higher As Conditions Stabilize
May 06, 2024 4:39 PM ETMiller Industries, Inc. (MLR)
Daniel Jones
(1)
Summary
Miller Industries, Inc. has seen a significant increase in share price, outperforming the S&P 500.
The company has experienced growth in revenue, profits, and cash flows, driven by supply chain improvements and strong customer demand.
Management is expected to announce financial results for Q1 2024 on May 8th, and investors should anticipate further increases in revenue, profits, and cash flows.
My name is Dan Jones. I have degrees in accounting and economics, and ran a registered investment advisor for nine years. I lead the investing group Crude Value Insights.
One of the best performing companies, from a share price appreciation perspective, over the past year or so has been Miller Industries, Inc. (NYSE:MLR). For those not familiar with the company, it focuses on the production and sale of towing and recovery equipment. Since I last reiterated my "Buy" rating on the stock in early February 2023, shares are up 94.4% compared to the 24.2% rise seen by the S&P 500. Even better, since I first rated the company a "Buy" in March 2022, the stock is up 104.3%. That dwarfs the 14.3% increase seen by the broader market over the same window of time.
This move higher has not been without a cause. Revenue, profits, and cash flows, have all increased nicely year over year. It is fair to question just how much additional upside could be on the table. But the fact of the matter is that, when you consider how far the company has come in such a short window of time, it's not difficult to imagine even further increases moving forward. This is not to imply that we will see a comparable amount of upside. That is unlikely because the easy money has already been made. But absent something unexpected occurring, I do think optimism is warranted.
Of course, as investors, it's incumbent upon us to be flexible. As new data comes in, our assessment of the picture should change. Sometimes, this will be for the better. Other times, it will be for the worse. It just so happens that management is expected to report financial results covering the first quarter of the 2024 fiscal year after the market closes on May 8th.
Unfortunately, analysts have not provided any guidance on the matter. However, there are certain metrics that investors would be wise to pay attention to as earnings near.
Massive upside achieved
As I mentioned already, the past year or so has been particularly pleasant for shareholders of Miller Industries. Revenue during the 2023 fiscal year, for instance, came in at $1.15 billion. That's an increase of 35.9% compared to the $848.5 million generated one year earlier. This move higher, according to management, was driven by higher production volumes that the company chalked up to supply chain improvements and strong customer demand. Although not as significant, it seems pricing increases also contributed to some of this. But of course, management did not provide any assessment of the impact of price increases.
On the bottom line, the situation looked even better. Net profits nearly tripled from $20.3 million to $58.3 million. While the increase in revenue for the company was instrumental in achieving this, an undeniably big impact came from some margin expansion. Notably, the firm's gross profit margin managed to increase from 9.7% to 13.2%. While this may not seem like much, when applied to the revenue generated last year, that's an extra $39.9 million in pretax profits for the firm. Supply chain stabilization permitted higher deliveries, which management attributed to the improvement.
Naturally, other profitability metrics moved higher as well. Operating cash flow went from negative $19.2 million to positive $11 million. Adjusted operating cash flow more than doubled from $34.2 million to $70.5 million. And finally, EBITDA generated by the enterprise rose from $41.4 million to $92 million.
All things considered, this is a rather impressive showing for the company. It also has helped to make the company more appealing from a valuation perspective. As an example, I would like to point to the chart above. In it, you can see how shares are valued using results from 2023 and from 2022. The stock has gotten a lot cheaper even though its share price has moved up. Now, in the table below, you can see the firm compared to five similar enterprises. On that basis, shares aren't exactly cheap. But they are far from expensive, with only two of the companies cheaper than it using each of the three valuation approaches.
Company Price / Earnings Price / Operating Cash Flow EV / EBITDA
Miller Industries 10.4 8.6 6.9
Westport Fuel Systems (WPRT) 6.9 N/A 17.7
Commercial Vehicle Group (CVGI) 4.1 5.2 4.8
Manitowoc (MTW) 11.5 7.2 5.6
Douglas Dynamics (PLOW) 20.4 11.5 10.7
Astec Industries (ASTE) 29.6 35.8 12.2
Whenever I see a big improvement like this, I have to ask myself whether the increase is temporary or part of a new normal. To not ask this and delve into it is to invite value traps. The good news for those who are bullish about the business is that this actually appears to be a reversion to how things were before the pandemic. By management's own admission, the business has struggled with inflationary pressures and supply chain problems recently. In its 2023 annual report, the company even acknowledges that it continues to see significant pressure on global supply chains. They also mentioned that inflation could continue to cause issues when it comes to foreign currency fluctuations that impact the company.
If you look at the chart below, however, it seems the worst is probably behind us. That chart shows the operating profit margin of the company from 2015 through 2023. Up through 2019, the picture was gradually improving year after year, with margins widening. The pandemic brought with it two very difficult years in 2021 and 2022. But now, with supply chain issues improving, and the company finally regaining pricing power, margins have rebounded to levels that are actually above what they were before the pandemic. It's not unthinkable that margins could decrease slightly to match what they were back then. But that would be only a small inconvenience compared to what the firm had seen in the prior couple of years.
There are also some other things working in the company's favor. For starters, in early April, management announced a new $25 million share buyback program. They also boosted their quarterly dividend by 5.6% in the last quarter. Both of these show that management is confident in the company's financial condition.
There could also be a catalyst that could help shareholders. In March of this year, the company publicly responded to a letter put out by Advisory Research, which has a stake in Miller Industries. That letter called for the company to form a special committee to conduct a strategic review process. This could result in a sale of the business, a part of the business, or even restructuring activities aimed at creating shareholder value. However, Advisory Research ultimately revealed to management that its end goal was to see the company sold. Management, citing the company's success over the past year or so, concluded that it is "proud of the current state" of the business. While I think the firm is right about this, you never know what kind of major transactions could come through the pipeline.
Although I don't expect anything to occur currently, any big development likely would come when earnings are released. And it just so happens that management is expected to announce financial results covering the first quarter of the 2024 fiscal year after the market closes on May 8th. Analysts have not provided any estimates of revenue or earnings. But in the table below, you can see how financials were during the first quarter of 2023. Considering how performance has been over the past year or so, and the fact that backlog for the company remains near all-time highs, I wouldn't be surprised if revenue, profits, and cash flows, are all higher year over year.
Takeaway
Based on the data provided, I believe that Miller Industries remains an attractive opportunity. I do think the easy money has been made. However, the stock is cheap enough, particularly on an absolute basis, to warrant additional upside in my book. Given these factors, and others, such as the new share buyback program, I believe that a soft "Buy" rating makes sense right now.
Editor's Note: This article covers one or more microcap stocks. Please be aware of the risks associated with these stocks.
Hweb- IDR
I was a bit preoccupied this morning and missed this one. Just curious- what PE going forward do you think it warrants. I just looked at Barrick Gold(GOLD), and huge competitor, and they are expecting 35% growth going forward, and selling for a 12 PE going forward fully taxed. IDR just made $.17 for the March qtr. Based on what I read from the CEO letter, it seems he expects growth to be huge. I wonder if there's any way to try and gauge what they might post in eps over the next few quarters.
I take it you're looking for CXDO to deliver some big Q1 numbers tomorrow after the bell? The Q4 bottom line was pretty underwhelming. Stock got whacked as a result. Can't get a sense of what to expect tomorrow. The 4/16/24 PR seems to bode well at least.
CSPI...Wednesday will be interesting. I'll be holding...(CSPI is currenty my #4 position).
CXDO is by far my #1 position, FTK @ #2, and SBOW @ #3.
IART- How low a PE before it's a buy ?
I guess if you don't believe the company, and think they lie, you should stay away. However if you believe them, then the company says they will post $3.06a avg in eps for 2024, with mid to upper single digit growth going forward. So now the question first is, what is an average PE in the medical device sector ? Answer about 25, and with upper single digit growth expected. So now, with all the negativity with IART, what would you pay ? Right now at $23, the PE is 7.5 going forward. At $20 it would be a 6.5 PE going forward.
Many here think there's something wrong, other than the closure of the Boston Factory for the last year- but what ? Could it be, fear of getting sued by someone who got hurt from the products recalled from the Boston Factory ? You would think if that was the case, we would have heard of something, being that the recall has been going on for about 1.5 years. Now what else could it be ? Could it be that the company has lost market share, and it's products are in decline. Well the company just made a recent acquisition, which they say is going great, and that all of their products are doing nicely, and expected to stay that way into 2025. So what could it be ? They even went on to say in the CC, that even the 2 products that were made in the Boston Factory still have high demand, and at some point they will start manufacturing them again. I mean their balance sheet is healthy, so what ?
OT: I wish I had a penny for every time a woman went to a nail salon....
SSKMP Managed Index (As Of 5/6/24)
Daily Performance
-0.73%
YTD Performance
+0.73%
Overall Performance
+475.36% (Including Options Trading +339.34%)
I still think holding into earnings is a losing proposition IF
you're a short term trader. Today I got wacked on IART, not only for holding into earnings, but by chasing bad news, thinking the valuation would matter. The longer I play the market, the more I can see why playing good news always gives more % gain potential than playing bad news, no matter what the valuation.
re. '..There seem to be a gazillion bank stocks out there..'
There are a gazillion banks just in the small town I live in. And nail salons.
BCBP - Thanks, SSKILLZ. Appreciate your analysis. I think you're the de facto bank expert on the board. I actually bought a couple books on investing in bank stocks. They're really not very thick, but I haven't gotten through them yet; so maybe I'm a little thick!
There seem to be a gazillion bank stocks out there, so knowing your way around their financial statements would be a good skill to have.
Good luck with IART. Hope it turns for you. Momentum seems to be a pretty powerful force in the market lately.
BCBP
The insider buying is a plus. As with everything there are pluses and minues.
BCBP Earned .32 down from .46 this time last year. Hence can't say that is a positive. But let break down all the metrics to get a better understanding of what is going on here.
Loan Growth and Deposit Growth Loan growth was down slightly sequentially and y/y. As for depsoti growth it has been going slightly higher and quite frankly that happened again in q1. All and all nothing here bothers me.
NIMS Otherwise known as Net interest margin, as one knows this has been dropping for all banks, I am looking for stabilization at this point, and eventually an increase of nims in the coming quarters on the banks i want to buy. The good news is nims went from 2.57% last quarter to 2.50% this quarter, which isn't good at face value, but it had a much slower drop than the previous quarter going from 2.78% to 2.57%, so maybe getting close to troughing. Obviously can't know that for certain, but that would be a plus if it stops going down, right now can't say that though as 1 number is not a trend and it was still going down, so need to see if nims comes in around here next quarter or it declines. Right now NIMS trend is still a negative, but it would be a plus if it is starting to trough for profitability and top line going foward. Not sure yet here if that is the case.
Book value Trades at steep discount too book, so that is a plus.
Dividend Pays a nice divy, than again not thrilled that the payout ratio is approaching 50% on current earnings. That too me is not a plus, although the divy is. How safe that divy is, if this continues is a slight concern.
Asset quality here is the thing that has kept me away from BCBP. Look at the trend of not just non accural Loans, but classified loans. Now clssified loans don't have to go bad, but they are seen as much higher risk, the number was just 17 million in q1 last year, now over 97 million in q1 this year, that is a huge increase. Of course Non accural have gone up significantly and based on what I think will happen they may go up alot further in future quarter would like to see some stabilization with some of these metrics first. Right now I see these numbers going up which is obviosuly a negative. Don't get me wrong asset quality is weaker for alot of banks than it was a year ago, and some of that is that it is coming off numbers where therere were very low levels of bad loans, but in this case, just see these numbers going up a bit faster than I would expect even in that environment.
Now why we should care is BCBP at some point might need to take larger provisions than say 2 million a quarter, and that has to be a concern. Plus asset quality is always the most important thing when you look at a bank.
All and all I would pass as I like numerous banks better than this. Asset quality is very important to me, the metric could be better and i'm being nice, specifically with the trend. Loan and deposit growth is non existant. don't think this should trade at much more than 10 multiple if that, and quite frankly wouldn't surprise me if earnings are under .30 next quarter, hence in the mid 10's it is near FV for me. The divy although great, the payout ratio is approaching 50% which doesn't make me thrilled either. The only real positive I see right now is the discount too book. Barring on the off chance of it being acquired (Not a reason to invest), the stock should remain at a steep discount too book until the EPS Numbers stop declining (if I had to guess next quarter would be under .30) so that would continue the trend of declining, and asset quality gets better which right now the metrics are getting worse. I'll pass, but I wish you the best with it. All is just my opinion, and I could always be wrong though.
I added some IDR as well. After it pulled back from over $9 earlier down to the $8.40's. Like the sound of this CEO quote from today's earnings PR-
Mr. Swallow concluded, "Over the past 10 years our team has built a truly unique business in the resources sector and now have the right assets in the right locations at the right time. We've produced a record Q1 and Q2 is off to a great start. It is gratifying to see the business reach this level of profitability and to be able to reinvest a meaningful amount into future growth initiatives. I am as energized as ever over the position and direction of the company, and I get to work alongside a group (including my two sons) whose efforts have a direct and positive impact on the communities where we operate. We are only in the early innings of a game we intend to win."
With gold over $2300/oz, they should be set up for excellent comps all year. Their rare earth element angle also gives this one some pump potential imo
Also from today's PR-
Idaho Strategic Resources (IDR) is an Idaho-based gold producer which also owns the largest rare earth elements land package in the United States. The Company's business plan was established in anticipation of today's volatile geopolitical and macroeconomic environment. IDR finds itself in a unique position as the only publicly traded company with growing gold production and significant blue-sky potential for rare earth elements exploration and development in one Company.
Followers
|
405
|
Posters
|
|
Posts (Today)
|
2
|
Posts (Total)
|
113995
|
Created
|
02/09/13
|
Type
|
Free
|
Moderator SSKILLZ1 | |||
Assistants hweb2 abh3vt wadegarret researcher59 Knowledge is King nelson1234 |
Posts Today
|
2
|
Posts (Total)
|
113995
|
Posters
|
|
Moderator
|
|
Assistants
|
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |